Affiliations: [a] Department of Psychiatry, Gil Medical Center, Gachon University, College of Medicine, Incheon, Korea
| [b] Incheon Metropolitan Dementia Center, Incheon, Korea
| [c] Neuroscience Research Institute, Gachon University, College of Medicine, Incheon, Korea
Correspondence:
[*]
Correspondence to: Byeong Kil Yeon, MD, PhD, Department of Psychiatry, Gil Medical Center, Gachon University School of Medicine, 21, 774 beon-gil, Namdong-daero, Namdong-gu, Incheon, 21565, Korea. Tel.: +82 32 460 9030; Fax: +82 32 472 3396; E-mail: [email protected]
Abstract: Stem cell therapy has been noted to be a disease-modifying treatment for Alzheimer’s disease (AD). After the failure to develop new drugs for AD, the number of studies on stem cells, such as mesenchymal stem cells (MSCs) and neural stem cells (NSCs), has increased from the early 2000 s. Issues pertaining to stem cells have been investigated in many animal studies in terms of stem cell origin, differentiation potency, method of culture, tumor formation, injection route, and mobility. Since 2010, mainly in East Asia, researchers began clinical trials investigating the use of stem cells for AD. Two phase I trials on moderate AD have been completed; though they revealed no severe acute or long-term side effects, no significant clinical efficacy was observed. Several studies, which involve more sophisticated study designs using different injection routes, well-established scales, and biomarkers such as amyloid positron emission tomography, are planned for mild to moderate AD patients. Here, we review the concept of stem cell therapy for AD and the progress of recent clinical trials.
